An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)

• Response rate [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Duration of response [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Recurrence rate [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Progression-free survival [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Overall survival [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Safety: Incidence of adverse events [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]

• Objective response rate [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Duration of objective response [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Recurrence rate [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Progression-free survival [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Overall survival [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]
• Safety: Incidence of adverse events [ Time Frame: approximately 5 years ] [ Designated as safety issue: No ]

This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome. The total study duration is anticipated to be a maximum of 8 years, including 3 years for patient recruitment and 5 years follow-up.

Patients treated for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome

Inclusion Criteria:

• Adult patients, >/= 18 years of age

• Patients with basal cell carcinoma (BCC) who meet either of the following definitions:

  • Patients who were determined with advanced disease (aBCC) within 90 days prior to study enrollment, have not been diagnosed with basal cell carcinoma nevus syndrome (BCCNS) and have not been treated with an investigational or approved hedgehog pathway inhibitor
  • Patients with aBCC who have not been diagnosed with BCCNS and who were previously treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)
  • Patients with BCCNS who either have aBCC or multiple BCCs of any stage as defined by protocol (may include patients previously enrolled in Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP))

Exclusion Criteria:

• Participation in a clinical trial within 90 days prior to study enrollment that has either involved treatment of aBCC or involved treatment with an investigational or approved hedgehog pathway inhibitor, except for patients treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)